Albertsons (ACI) Q4 2025 earnings review
Life After Kroger: Financial Engineering Masks a Stalling Core Business
With the Kroger merger officially dead, Albertsons is pivoting hard to a standalone strategy heavily reliant on financial engineering. Management authorized a massive 13% dividend hike and expanded buybacks to $2 billion, signaling confidence. However, the operational reality is grim: Identical (ID) sales growth crashed to 0.7% in Q4, down sharply from 2.8% at the start of the year. Worse, the very segment that drove early-year growth—pharmacy—has reversed into a major liability due to new Medicare drug pricing rules, creating a 150-basis-point headwind for FY26. While adjusted EPS is guided slightly higher next year, it is being propped up by debt-funded share repurchases as EBITDA stalls.
🐂 Bull Case
Management is aggressively returning cash to shareholders, boasting a 13% dividend increase and a fresh $2 billion buyback authorization. With the Kroger deal gone, Albertsons is deploying its balance sheet to manufacture EPS growth.
Loyalty membership hit 51.2 million (up 12% YoY). These highly engaged customers shop more frequently and power the high-margin Albertsons Media Collective, providing a crucial profit buffer.
🐻 Bear Case
Pharmacy previously masked grocery unit weakness. Now, the Inflation Reduction Act's Medicare pricing changes have severely impaired pharmacy margins and revenue, dragging FY26 ID sales guidance down by 150 basis points.
Despite a massive $1.5 billion productivity plan, FY26 Adjusted EBITDA guidance ($3.85B-$3.925B) is functionally flat compared to FY25 ($3.90B) and down from FY24 ($4.00B). Inflation and digital delivery costs are eating all operational savings.
⚖️ Verdict: 🔴
Bearish. Management's narrative of a "New Day" and "disciplined execution" is contradicted by flattening EBITDA and sharply decelerating identical sales. Buying back stock with borrowed money while the core business slows to near-zero growth is a fragile long-term strategy.
Key Themes
The Macro Pharmacy Shock
Reversing. For the first half of the year, pharmacy sales surged ~20% YoY, acting as Albertsons' primary growth engine. That engine has seized. The Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program hit in January 2026, causing worse-than-expected pricing headwinds and mix shifts. Management explicitly stated this will drag down FY26 total Identical Sales by an massive 150 basis points.
Digital Sales Are Decelerating
Decelerating. E-commerce has been management's favored talking point, but the momentum is fading. Digital sales growth dropped sequentially every single quarter this year: 25% (Q1) -> 23% (Q2) -> 21% (Q3) -> 16% (Q4). Despite this slowdown, delivery and handling costs continue to pressure core gross margins, which fell 25 basis points (ex-fuel/LIFO) in Q4.
Financial Engineering Accelerates EPS
Accelerating. With organic EBITDA growth completely stalled out, Albertsons is pulling financial levers to grow earnings per share. In Q4 alone, they issued $2.1 billion in new notes, executing an Accelerated Share Repurchase (ASR) program that retired 42.7 million shares. Consequently, the net debt ratio has climbed from 1.88x a year ago to 2.24x today.
The $774 Million Opioid Anchor
A sudden, massive reality check on legacy liabilities: Albertsons recorded a $773.8 million pre-tax loss ($600M net of tax) related to a nationwide Opioid Settlement Framework. This single charge completely wiped out Q4 GAAP profitability, resulting in a net loss of $0.94 per share. While payable over nine years, it represents a real drain on future cash flows.
Productivity Engine Funding Investments
Stable. The company remains highly reliant on its $1.5 billion productivity program (running FY25-FY27) to stay afloat. Driven by supply chain automation—targeting 30% of warehouse volume by end-of-year—and AI-agent deployments for pricing, these savings are entirely consumed by wage inflation and necessary price investments to keep value-conscious shoppers from leaving.
Loyalty Loop Monetization
Accelerating. Despite identical sales stalling, Albertsons successfully grew its loyalty membership by 12% to 51.2 million. This vast, engaged data pool is the vital fuel for the Albertsons Media Collective (AMC), their high-margin retail media network, which continues to offset the brutal margin economics of digital grocery delivery.
Other KPIs
Accelerating. Up significantly from 1.88x at the end of FY24. The transition back to a standalone company involves aggressive share repurchases ($1.5B spent in FY25) funded partly by balance sheet leverage. While 2.24x remains manageable for a grocer, the trajectory indicates less dry powder for future M&A or price wars.
Stable. Operating cash flow came in at $2.37B (down from $2.68B in FY24), against CapEx of $1.84B. This leaves tight free cash flow generation relative to the aggressive scale of dividend payouts ($322M) and buybacks ($1.48B). Albertsons is dipping into debt and existing cash balances to fund shareholder returns.
Guidance
Decelerating. A sharp drop from FY25's 2.0% growth. This near-zero outlook is heavily weighed down by a massive 150 basis point drag from the IRA Medicare drug pricing rules on the pharmacy segment. Stripping out the pharmacy hit, core grocery comps are implied at 1.5% to 2.5%, roughly flat.
Stable. The midpoint ($3.88B) is virtually identical to FY25's $3.90B output. This lays bare a troubling reality: all of the company's stated $1.5 billion productivity savings are being entirely vaporized by structural mix shifts toward low-margin digital sales, wage inflation, and pharmacy headwinds. No operating leverage is occurring.
Accelerating. Despite flat EBITDA, EPS is guided higher than FY25's $2.18. This exposes the core strategy: aggressive, debt-fueled share buybacks are artificially lifting per-share metrics while the actual business operations tread water.
Accelerating. An increase from FY25's $1.84B. Management is forced to pour more cash into digital platforms and supply chain automation to remain competitive against Walmart and Amazon, further squeezing free cash flow.
Key Questions
Pharmacy Headwind Duration
You guided for a 150-basis-point hit to ID sales from the IRA Medicare rules in FY26. Is this a one-time step-down in the baseline, or do you anticipate multi-year structural pressure on pharmacy margins and volumes?
Digital Profitability Timeline
Digital sales growth decelerated steadily from 25% in Q1 to 16% in Q4, yet delivery and handling costs continue to pressure gross margins. At what digital penetration level does this segment reach margin parity with the physical store?
Capital Allocation Limits
Net debt jumped to 2.24x to help fund the $1.5B in share repurchases this year. With CapEx guided up to $2.2B next year and flat EBITDA, how much further are you willing to stretch the balance sheet to fund the remaining $2B buyback authorization?